We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.06B
Turnover
46.34%
1-Year Est. Return
215.32%
This Fund
S&P 500
This Quarter
Est. Return
+11.43%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$990M
AUM Growth
-$95.1M
(-8.8%)
Cap. Flow
-$12.4M
Cap. Flow
% of AUM
-1.25%
Top 10 Holdings %
Top 10 Hldgs %
70.6%
Holding
53
New
12
Increased
7
Reduced
12
Closed
14
Avg Time Held Equity + Options
0.7
years
Top 10 Avg Time Held Equity + Options
0.9
years
Top 20 Avg Time Held Equity + Options
0.7
years
Avg Time Held Equity only
0.7
years
Top 10 Avg Time Held Equity only
1
year
Top 20 Avg Time Held Equity only
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kyntra Bio
KYNB
|
+$58.8M |
| 2 |
Morphic Holding, Inc. Common Stock
MORF
|
+$42.9M |
| 3 |
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
|
+$34.9M |
| 4 |
BCEL
Atreca, Inc. Class A Common Stock
BCEL
|
+$26.8M |
| 5 |
KRSA
Korsana Biosciences, Inc. Common Stock
KRSA
|
+$11M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$42.5M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$31.3M |
| 3 |
argenx
ARGX
|
+$31M |
| 4 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$24.9M |
| 5 |
Dianthus Therapeutics
DNTH
|
+$21M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.05% |
| 2 | Miscellaneous | 1.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
SURF
26
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $6.52M | 0.66% |
2,312,688
+49,200
| +2% | +$196K |
2018 Q2
4 quarters
|
|
27
DELISTED
Mersana Therapeutics
MRSN
| $5.64M | 0.57% |
55,689
-36,311
| -39% | -$4.28M |
2019 Q1
1 quarter
|
|
28
Curis
CRIS
$1.39M
| $5.55M | 0.56% |
7,456
| – | – |
2018 Q4
2 quarters
|
|
29
Neurogene
NGNE
$483M
| $5.35M | 0.54% |
113,294
| – | – |
2018 Q2
4 quarters
|
|
30
Rhythm Pharmaceuticals
RYTM
$6.1B
| $4.91M | 0.5% |
223,167
-177,671
| -44% | -$4.49M |
2018 Q4
2 quarters
|
|
31
Solid Biosciences
SLDB
$607M
| $4.75M | 0.48% |
+55,133
| New | +$6.01M |
2019 Q2
0 quarters
|
|
|
NGM
32
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $4.64M | 0.47% |
+316,900
| New | +$4.64M |
2019 Q2
0 quarters
|
|
33
DELISTED
Kezar Life Sciences
KZR
| $4.5M | 0.45% |
58,329
-27,318
| -32% | -$4.25M |
2018 Q2
4 quarters
|
|
|
KDNY
34
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $2.71M | 0.27% |
352,284
-35,594
| -9% | -$542K |
2019 Q1
1 quarter
|
|
35
Vericel Corp
VCEL
$2.12B
| $2.48M | 0.25% |
131,001
| – | – |
2019 Q1
1 quarter
|
|
36
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $2.3M | 0.23% |
+24,848
| New | +$1.73M |
2019 Q2
0 quarters
|
|
37
DELISTED
Regulus Therapeutics
RGLS
| $1.39M | 0.14% |
+111,111
| New | +$1.28M |
2019 Q2
0 quarters
|
|
|
GMDA
38
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
| $265K | 0.03% |
+52,120
| New | +$409K |
2019 Q2
0 quarters
|
|
|
TCRR
39
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $231K | 0.02% |
+16,114
| New | +$257K |
2019 Q2
0 quarters
|
|
40
Arbutus Biopharma
ABUS
$844M
| – | – |
-2,172,883
| Closed | -$7.78M | – |
|
41
Arvinas
ARVN
$465M
| – | – |
-50,000
| Closed | -$738K | – |
|
42
Assembly Biosciences
ASMB
$419M
| – | – |
-96,133
| Closed | -$18.3M | – |
|
|
43
Ascendis Pharma A/S
ASND
$14.9B
| – | – |
-360,819
| Closed | -$42.5M | – |
|
|
44
PUT
Ascendis Pharma A/S
ASND
$14.9B
| – | – |
-360,000
| Closed | -$42.4M | – |
|
|
45
Dianthus Therapeutics
DNTH
$4.11B
| – | – |
-79,862
| Closed | -$21M | – |
|
|
46
PUT
Kyntra Bio
KYNB
$22.1M
| – | – |
-40,000
| Closed | -$54.4M | – |
|
47
CALL
Ironwood Pharmaceuticals
IRWD
$620M
| – | – |
-1,295,012
| Closed | -$14.7M | – |
|
48
Rocket Pharmaceuticals
RCKT
$254M
| – | – |
-450,000
| Closed | -$7.89M | – |
|
49
Scholar Rock
SRRK
$4.92B
| – | – |
-338,668
| Closed | -$6.36M | – |
|
50
Zai Lab
ZLAB
$2.64B
| – | – |
-78,519
| Closed | -$2.32M | – |
|
Similar funds
RHJA
ST
ABTD
CFA
DWT
RMC
SIC
FWTB
EcoR1 Capital's Q2 2019 Portfolio in Review
As of Q2 2019, EcoR1 Capital held 53 positions worth $990M, down 8.8% from $1.08B the previous quarter. Its ten largest holdings account for 71% of the portfolio.
EcoR1 Capital's Q2 2019 filing shows 12 new, 7 increased, 12 reduced and 14 closed positions. Its largest new stake was Morphic Holding, Inc. Common Stock: 2,266,804 shares worth $44.9M. The largest sale was Ascendis Pharma A/S, an estimated $42.5M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 85% a quarter earlier, followed by Miscellaneous.
- EcoR1 Capital's largest Q2 2019 buy was Morphic Holding, Inc. Common Stock: 2,266,804 shares worth $44.9M.
- EcoR1 Capital added most to Kyntra Bio in Q2 2019, an estimated $58.8M increase.
- EcoR1 Capital's biggest Q2 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $31.3M.
- EcoR1 Capital fully exited Ascendis Pharma A/S in Q2 2019, selling an estimated $42.5M.
- EcoR1 Capital's ten largest holdings make up 71% of its $990M portfolio in Q2 2019.
- EcoR1 Capital opened 12 new positions and closed 14 in Q2 2019.
- EcoR1 Capital's portfolio value fell 8.8% quarter-over-quarter to $990M.
Based on EcoR1 Capital's 13F filing for Q2 2019, filed 14 Aug 2019.